| Specificity |
The product is specific for Nivolumab. The antibody is recommended as a capture antibody in a pharmacokinetic (PK) bridging assay with detection antibody GenScript, A01848-40, Anti- Nivolumab Antibody (6G5H2E6), mAb, Mouse. |
| Host Species |
Mouse |
| Immunogen |
Nivolumab |
| Conjugate |
Unconjugated |
|
Working concentrations for specific applications should be determined by the investigators. The appropriate concentrations may be affected by secondary antibody affinity, antigen concentration, the sensitivity of the method of detection, temperature, the length of the incubations, and other factors. The suitability of this antibody for applications other than those listed below has not been determined. The following concentration ranges are recommended starting points for this product. |
| Application |
Recommended Usage |
| ELISA |
0.01-0.1 µg/ml |
|
| Form |
Lyophilized |
| Storage Buffer |
lyophilized with PBS, pH 7.4, containing 0.02% sodium azide. |
| Reconstitution |
Reconstitute the lyophilized powder with deionized water (or equivalent) to an final concentration of 0.5 mg/mL. |
| Storage Instructions |
The lyophilized product remains stable up to 1 year at -20 °C from date of receipt. Upon reconstitution, it can be stored for 2-3 weeks at 2-8 °C or for up to 12 months at -20 °C or below. Avoid repeated freezing and thawing cycles. |
| Purification |
Protein A affinity column |
| Isotype |
Mouse IgG1 |
| Clonality |
Monoclonal |
| Clone ID |
8G6G3D8 |
Anti-Nivolumab Antibody (8G6G3D8), mAb, Mouse (GenScript, A01847-40) binds with Nivolumab, while the antibody does not recognize human IgG Fc fragment (data not shown).
Coating antigen: Nivolumab, 1 µg/ml.
Anti-Nivolumab antibody (GenScript, A01847-40) dilution start from 1,000 ng/ml.
EC₅₀= 2.72 ng/ml.
Anti-Nivolumab Antibody (8G6G3D8), mAb, Mouse (GenScript, A01847-40) binds with Nivolumab,while the antibody does not recognize human IgG Fc fragment (data not shown).
Coating antigen: Nivolumab, 1 µg/ml.
Anti-Nivolumab antibody (GenScript, A01847-40) dilution start from 1,000 ng/ml.
EC₅₀= 2.72 ng/ml.
Anti-Nivolumab Antibody (8G6G3D8), mAb, Mouse (GenScript, A01847-40) binds with Nivolumab, while the antibody does not recognize human IgG Fc fragment (data not shown).
Coating antigen: Nivolumab, 1 µg/ml.
Anti-Nivolumab antibody (GenScript, A01847-40) dilution start from 1,000 ng/ml.
EC₅₀= 2.72 ng/ml.
| Target Background |
Nivolumab (Opdivo) is a humanized monoclonal antibody that is approved by the U.S. Food and Drug Administration for the treatment of patients with unresectable or metastatic melanoma. Nivolumab binds to the human cell surface receptor PD-1 (Programmed Cell Death Protein 1) and blocks its interaction with PD-L1, resulting in the activation of T-cell-mediated immune responses against tumor cells.GenScript Anti-Nivolumab Antibody (8G6G3D8), mAb, Mouse is produced from a hybridoma resulting from the fusion of partner and B-lymphocytes obtained from a mouse immunized with Nivolumab. |
| Synonyms |
Mouse monoclonal to Opdivo |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
